Kura Oncology Inc [NASDAQ: KURA] gained 1.80% on the last trading session, reaching $9.05 price per share at the time.
If compared to the average trading volume of 2.04M shares, KURA reached a trading volume of 2675719 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Kura Oncology Inc [KURA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KURA shares is $27.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KURA stock is a recommendation set at 1.31. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Kura Oncology Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 24, 2024. While these analysts kept the previous recommendation, Stifel dropped their target price from $26 to $19. The new note on the price target was released on October 14, 2024, representing the official price target for Kura Oncology Inc stock. Previously, the target price had yet another raise to $26, while Mizuho analysts kept a Buy rating on KURA stock.
The Average True Range (ATR) for Kura Oncology Inc is set at 0.48 The Price to Book ratio for the last quarter was 1.66, with the Price to Cash per share for the same quarter was set at 5.85.
Trading performance analysis for KURA stock
Kura Oncology Inc [KURA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.69. With this latest performance, KURA shares gained by 3.67% in over the last four-week period, additionally sinking by -52.01% over the last 6 months – not to mention a drop of -57.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KURA stock in for the last two-week period is set at 59.04, with the RSI for the last a single of trading hit 71.79, and the three-weeks RSI is set at 49.33 for Kura Oncology Inc [KURA]. The present Moving Average for the last 50 days of trading for this stock 9.03, while it was recorded at 8.43 for the last single week of trading, and 17.09 for the last 200 days.
Kura Oncology Inc [KURA]: A deeper dive into fundamental analysis
Kura Oncology Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.47 and a Current Ratio set at 11.47.
Kura Oncology Inc [KURA]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KURA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Kura Oncology Inc go to 3.73%.
An analysis of Institutional ownership at Kura Oncology Inc [KURA]
There are presently around $113.93%, or 115.25%% of KURA stock, in the hands of institutional investors. The top three institutional holders of KURA stocks are: SUVRETTA CAPITAL MANAGEMENT, LLC with ownership of 7.07 million shares, which is approximately 8.4258%. BLACKROCK INC., holding 6.97 million shares of the stock with an approximate value of $$143.43 million in KURA stocks shares; and BLACKROCK INC., currently with $$119.56 million in KURA stock with ownership which is approximately 6.9208%.
